Table 2.
Distribution of selected characteristics of Caucasian population-based prostate cancer cases used for SLCO2B1 and SLCO1B3 SNP genotype analyses
| Total cases | 1,309 |
| Age | |
| 40-49 | 102 (7.8) |
| 50-54 | 189 (14.4) |
| 55-59 | 325 (24.8) |
| 60-64 | 395 (30.2) |
| 65-69 | 153 (11.7) |
| 70-74 | 145 (11.1) |
| Family history of prostate cancer * | |
| Negative | 1026 (78.4) |
| Positive | 283 (21.6) |
| PSA tests within 5 years prior to diagnosis | |
| None | 288 (22.1) |
| 1 – 2 | 320 (24.5) |
| 3+ | 638 (48.9) |
| Unknown | 58 (4.5) |
| BMI (weight/height2) | |
| < 25.0 | 429 (32.8) |
| 25.0 – 29.9 | 638 (48.7) |
| >= 30.0 | 242 (18.5) |
| Smoking status | |
| Never | 523 (40.0) |
| Former | 631 (48.2) |
| Current | 155 (11.8) |
| Diagnostic PSA (ng/mL) | |
| 0.0 – 3.9 | 178 (13.6) |
| 4.0 – 9.9 | 722 (55.2) |
| 10.0 – 19.9 | 191 (14.6) |
| >= 20 | 118 (9.0) |
| Missing | 100 (7.6) |
| Gleason score | |
| 2 – 6, 3+4 | 1103 (84.5) |
| 4+3, 8 – 10 | 202 (15.5) |
| Tumor stage | |
| Local | 1023 (78.2) |
| Regional | 254 (19.4) |
| Distant | 32 (2.4) |
| Treatment | |
| RP | 770 (58.8) |
| XRT +/− Hormones | 359 (27.4) |
| AD | 61 (4.7) |
| Other | 4 (0.3) |
| Watchful Waiting | 115 (8.8) |
*
First-degree family history of prostate cancer